Our Story
In 2015, modalities were changing, pharma was outsourcing R&D at higher rates and acquisition became a primary pathway for innovation. Science was moving faster and would increasingly require skillsets and infrastructures that allowed resources and environments to change as quickly as the research did. We realized the way science was being supported was not going to work in the future.
We thought about how to make science better, faster, and more effective. We explored how to use data and new technologies to develop, operate, and deploy resources for the next generation of science.
We imagined having any kind of lab, at any size, available immediately, with no lease, build out, or infrastructure required. We envisioned an enterprise lab platform where scientists could do any type of research on-demand.
Then we created it.
We built a novel program with flexibility, which allows your team to work in a private lab configured to your specific research needs, that can be made ready within weeks and adapt and change as quickly as your science evolves.
For the first time, our Labs as a Service framework lets you outsource your lab's infrastructure, but retain your scientists, workflows, and intellectual property.
That’s how we transformed labs into SmartLabs.
Why we do what we do
What do we care about?
Why do we get up in the morning?
This is what it boils down to.

MISSION
To benefit health and humanity, we radically transform how the world uses labs spaces by delivering customized labs that deploy within weeks, and can grow and change as quickly as research needs evolve.
VISION
To accelerate the pace of science for everyone, everywhere.
PURPOSE
To accelerate the number of effective therapeutics available in the market when we need them and when our loved ones need them.
Our Leadership
October 24,2023

Amrit Chaudhuri
Chief Executive Officer/ Co-Founder



Amrit Chaudhuri
Chief Executive Officer/ Co-Founder
Amrit spent his first eight years in the industry working with hundreds of R&D leaders at universities, biotechs, and large pharma companies to develop commercial products from discovery to market approval.
- Founded Advanced Peptides in 2007, a biopharma CRO
- Holds patents in chemistry for global commercialized products
- One of INC Magazine’s top 20 innovators in healthcare

Seth Taylor, PhD
Chief Business Officer/Co-Founder



Seth Taylor, PhD
Chief Business Officer/Co-Founder
Seth spent his first six years in the industry working in corporate business development and as a startup entrepreneur in high throughput biology, followed by 12 years as a growth strategy consultant for Fortune 500 biopharma.
- In 1999 founded Molecularware, winning the MIT 50K competition, and successfully exited in 2003
- As Principal at TSG partners and Managing General Partner at Vectur LLC, Seth focused on corporate growth and buy-side M&A, as well as VC backed startup sell-side M&A

Amelia Newbury
Executive VP of People and Process



Amelia Newbury
Executive VP of People and Process
Amelia has more than 20 years of experience creating and growing businesses. She has launched and grown five companies from start-up to success by creating winning strategies and high-performance teams that drive growth. Amelia has a unique understanding of how to structure people, culture, and process to fuel high-growth companies.
- Culture and people management expert for early-stage and post Series B companies; has held multiple C-level titles
- Previously Associate Partner and Pharma industry consultant for Monitor Group (now Monitor Deloitte)

Brian Taylor
Executive VP of Biopharma Solutions



Brian Taylor
Executive VP of Biopharma Solutions
Brian is a biopharmaceutical manufacturing expert with more than 20 years of experience in the industry. He comes to SmartLabs from a mid-sized molecular engineering company, where he ran their healthcare business. Prior to that, he was the GM for GE Healthcare’s Biomanufacturing Solutions business.
- Developed turnkey manufacturing solutions for mAb production with a single use platform
- Worked with Congress to bring generic manufacturing back to the US
- Launched and ran cGMP sites, most recently a facility in Spain

Saquib Butt
SVP of Infrastructure & Assets



Saquib Butt
SVP of Infrastructure & Assets
Saquib came to SmartLabs from Boston Scientific, where he was the Head of Global Design and Construction. Saquib has more than 20 years of experience building R&D Laboratory and GMP manufacturing facilities, including the new 500K SQFT Boston Scientific facility in Malaysia.
- Prior responsibilities of managing 9M SQFT across 150 sites in 12 countries
- Led design and construction of over 2M SQFT
- Experience rooted in commercial clean rooms, FDA validated GMP, R&D facilities, and utility infrastructures

Clement Fourny
SVP of Commercial



Clement Fourny
SVP of Commercial
Clement has a 12-year diverse experience in the Healthcare/Life Science industry. Before joining SmartLabs, Clement spent his career at GE and Danaher where he built a track record of strong achievements and execution in sales, commercial operations and operational finance, mobilizing high-performing cross-functional teams to deliver sustainable growth and drive company goals. In his prior role at Cytiva (previously known as GE Life Science), Clement was responsible for strategically supporting the global commercial organization of 3,000 associates with best-in-class sales operations services.
- Designed comprehensive incentive compensation and sales territory management strategies to support the integration of Cytiva and Pall Life Sciences
- Drove the complete financial execution and stewardship of >20 single-use technology bio-manufacturing turnkey projects to enable customer's access to cGMP capacity for mABs and vaccines manufacturing
- Led the commercial task force assembled to respond to the unique needs of Cytiva's customers during the COVID-19 crisis

Robin Feeney
VP of Accounting and FP&A



Robin Feeney
VP of Accounting and FP&A
Robin came to SmartLabs with over 30 years of experience in auditing and developing finance functions at various companies, focusing the last thirteen years on Biotechnology and Healthcare. Beginning her career at Big Four firms PwC and Deloitte, then global companies Bank of America and Fidelity Investments, she applies her internal controls and financial operations expertise to develop and strengthen financial functions and ensure scalability for growth while aligning with overall corporate strategies.
- Raised more than $350 million in debt and equity financing, working closely with Private Equity and Investment Banking on a variety of M&A transactions
- The first CFO at StrataDx, Robin helped the company more than double revenue during her tenure
- Developed and led a new department at Bank of America to oversee reconciliation and financial controls of the Bank’s internal deposit and general ledger accounts

Cole Young
General Counsel



Cole Young
General Counsel
Cole has represented SmartLabs since its formation, where his civil engineering background and legal expertise have been an integral part of the company’s growth over the years. Prior to joining SmartLabs, Cole was in private practice where he represented local, national, and international clients in construction and real estate projects.
- Negotiated and closed over 1M square feet of laboratory, office, manufacturing, and industrial space on behalf of national and international clients.
- Frequent panelist and speaker on construction and real estate.
- Successfully litigated, tried, and appealed several construction and real estate cases in multiple jurisdictions.
- Previously acted as corporate counsel for several national companies.

Dipankar Ghosh
VP of BioPharma Solutions



Dipankar Ghosh
VP of BioPharma Solutions
Dipankar is a Life Sciences Technology & Laboratory operations expert with more than 20 years of global experience in the industry. He comes to SmartLabs from a mid-sized MedTech devices company where he ran future products development. Prior to that, he spent 15+ years with Thermo Fisher Scientific in Europe and NA, holding key leadership positions responsible for technologies, public-private customer partnerships, and commercial growth as part of a $2.5B division.
- Created Applied Markets business segment for Thermo Fisher Scientific, and grew it at above market rate to $250M annual revenue
- Launched multiple products in the Life Sciences diagnostics instruments space, the most successful portfolio becoming a global $1B brand in 10 years
- Led development of Key Opinion Leaders with academia, industry and regulatory agencies for key research innovations and technology creation

Claus Weisemann
SVP of Quality



Claus Weisemann
SVP of Quality
Claus is a seasoned biopharmaceutical professional with over 30 years of industry expertise. He recently joined SmartLabs following his successful tenure at NGM Biopharmaceuticals, where he established and led an exceptional Quality team. Claus provided phase-appropriate and science-based Quality solutions to drive business success. Prior to this, Claus held influential Quality leadership positions in both biotech and pharmaceutical companies. His extensive background encompasses a wide range of organizations, from small to midsize biotech firms to large enterprises, covering the entire spectrum from early development to commercial production. Claus earned his PhD in Chemistry from the University of Ulm, Germany, and holds multiple patents in Biosensors, process development, and pharmaceutical formulations.
- Established and guided efficient, science-based QA and QC teams in various organizations, spanning development, commercial, and corporate environments.
- Led successful GMP inspections by FDA and other health authorities, including remediation of complex compliance issues.
- Coined “Intelligence Compliance” for a science- and risk based phase appropriate approach to Quality